Key facts
- This page summarizes Jeffrey Stein's Form 4 filing for Cidara Therapeutics, Inc. (CDTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jun 2024, 18:26.
Jeffrey Stein - 07 Jun 2024 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- CDTX
- Reported as of
- 07 Jun 2024
- Net transaction value
- +$105,680
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2024, 18:26:28 UTC
- Prior SEC filing
- 31 May 2024
- Next SEC filing
- 02 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shane Ward, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Stein filed Form 4 for Cidara Therapeutics, Inc. (CDTX) on 11 Jun 2024.
Change
- Previous filing in this sequence was filed on 31 May 2024.
- Current net transaction value: +$105,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDTX
transaction
Common Stock
Purchase
- Transaction value
- $105,680
- Shares
- +8,000
- Change %
- +48%
- Price
- $13.21
- Shares after
- 24,580
- Date
- 07 Jun 2024
- Ownership
- By trust
- Footnotes
- F1, F2
CDTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 57,884
- Date
- 07 Jun 2024
- Ownership
- Direct
- Footnotes
- F2, F3
CDTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,100
- Date
- 07 Jun 2024
- Ownership
- By son
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.05 to $13.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Footnote F2
The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
Footnote F3
Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024.